Next-generation, selective kinase medicines

Our proprietary scientific platform enables us to rapidly and reproducibly design medicines that selectively target kinase drivers of disease, enabling improved potency, less off-target activity and an increased probability of clinical success.

Blueprint Medicines’ avapritinib, an investigational KIT and PDGFRA inhibitor for advanced gastrointestinal stromal tumors (GIST) and systemic mastocytosis (SM)

Sutent® (sunitinib), an FDA-approved multi-kinase inhibitor for advanced GIST

Rydapt® (midostaurin), an FDA-approved multi-kinase inhibitor for advanced SM

Kinome illustrations reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).

A focused strategy

Our research focuses on kinase targets where we believe our technology can lead to meaningful improvements in treatment.

Difficult-to-drug

Well-recognized kinases that are difficult to target with existing technologies

Treatment-resistant

Mutant kinases that have become resistant to current treatments

Novel biology

New targets identified with our computational and cell biology expertise